Discussion on the Issues and Countermeasures in Clinical Trial Insurance / 中国医学伦理学
Chinese Medical Ethics
;
(6): 328-330,335, 2017.
Artículo
en Chino
| WPRIM
| ID: wpr-606266
ABSTRACT
Through analyzing the current situation and coverage controversy of Chinese clinical trial insurance,this paper stated that the attending insurance rate in domestic clinical trials was entirely low.The sponsors,clinical trial institutions,investigators and insurance companies paid attention of different levels to clinical trial insurance.Therefore,the risk awareness of drug/medical device clinical trials should be enhanced.It is necessary to give impetus to clinical trial insurance system,during which all parties need to make a joint effort including government departments,ethics committees,sponsors,clinical trial institutions,investigators and insurance companies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Chino
Revista:
Chinese Medical Ethics
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS